FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3188160477> ?p ?o ?g. }

• W3188160477 abstract "You have accessJournal of UrologyLate-breaking Abstract II - Malignant1 Sep 2021LBA02-06 PROSPECTIVE EVALUATION OF 18F-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF 18F-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES Hong Song, Judy Nguyen, Farshad Moradi, Carina Mari Aparici, Ben Franc, Guido Davidzon, and Andrei Iagaru Hong SongHong Song More articles by this author , Judy NguyenJudy Nguyen More articles by this author , Farshad MoradiFarshad Moradi More articles by this author , Carina Mari ApariciCarina Mari Aparici More articles by this author , Ben FrancBen Franc More articles by this author , Guido DavidzonGuido Davidzon More articles by this author , and Andrei IagaruAndrei Iagaru More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002149.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We prospectively evaluated a PET agent targeting prostate specific membrane antigen (PSMA), 18F-DCFPyL, in a single center study for detecting recurrent lesions in prostate cancer patients with biochemical recurrence (BCR). METHODS: We prospectively enrolled 223 men (49-91 years old, mean ± SD: 69.8±8.1) with biochemical recurrence (PSA median 2.0 ng/mL, range 0.12 to 698.4) after primary definitive treatment with prostatectomy (72%), radiotherapy (28%) or both (25%). The 18F-DCFPyL positive lesions compatible with prostate cancer were evaluated by two independent readers. Patients with possible extra-pelvic oligometastases (1-3 lesions with 18F-DCFPyL uptake) were identified. The maximum standardized uptake values (SUV max) of 18F-DCFPyL in these lesions were measured and used to categorize lesions into high uptake (SUV max ≥parotid gland SUV mean), moderate uptake (parotid gland SUV mean >SUV max ≥liver SUV mean) and mild uptake (liver SUV mean >SUV max ≥blood pool SUV mean). RESULTS: 18F-DCFPyL PET/CT had an overall positivity rate of 84% (172 scans), which increased with higher prostate specific antigen (PSA) levels (ng/mL): 62% (PSA <0.5), 77% (0.5 ≤PSA <1), 90% (1 ≤PSA <2), 92% (2 ≤PSA <5) and 96% (PSA ≥5), respectively. In the cohort who underwent prostatectomy, 18F-DCFPyL PET/CT had a higher positivity rate in patients with shorter PSA doubling time (PSAdt) (93% in PSAdt 0-3 months vs. 63% in PSAdt >12 months, p <0.01). Higher positivity rate was also observed in prostatectomy patients with high Gleason score (GS) (92% in GS 8-10 vs 71% in 72% in GS 6-7, p <0.01). No difference of 18F-DCFPyL positivity rate was observed in post-radiation patients with different PSAdt or GS. We identified 62 patients (28%) with a total of 109 possible extra-pelvic oligometastases. Among them, there are 60 osseous lesions (8 high, 16 moderate and 36 mild uptake), 40 lymph nodes (9 high, 13 moderate and 18 mild uptake) and 9 other lesions such as lung nodules (6 high, 2 moderate and 1 mild uptake). 27 out of the 62 patients (44%) received locally targeted therapy for these lesions (radiation therapy or surgery) with or without androgen deprivation therapy. CONCLUSIONS: 18F-DCFPyL PET/CT holds great potential to be a “one-stop shop” diagnostic tool in the work-up of BCR prostate cancer to identify possible extra-pelvic oligometastases for locally targeted therapy. Source of Funding: Progenics Pharmaceuticals © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1177-e1178 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hong Song More articles by this author Judy Nguyen More articles by this author Farshad Moradi More articles by this author Carina Mari Aparici More articles by this author Ben Franc More articles by this author Guido Davidzon More articles by this author Andrei Iagaru More articles by this author Expand All Advertisement Loading ..." @default.
• W3188160477 created "2021-08-16" @default.
• W3188160477 creator A5010216956 @default.
• W3188160477 creator A5016095722 @default.
• W3188160477 creator A5016115173 @default.
• W3188160477 creator A5018382697 @default.
• W3188160477 creator A5020773624 @default.
• W3188160477 creator A5034705511 @default.
• W3188160477 creator A5051525187 @default.
• W3188160477 date "2021-09-01" @default.
• W3188160477 modified "2023-09-27" @default.
• W3188160477 title "LBA02-06 PROSPECTIVE EVALUATION OF ¹⁸ F-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF ¹⁸ F-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES" @default.
• W3188160477 doi "https://doi.org/10.1097/ju.0000000000002149.06" @default.
• W3188160477 hasPublicationYear "2021" @default.
• W3188160477 type Work @default.
• W3188160477 sameAs 3188160477 @default.
• W3188160477 citedByCount "0" @default.
• W3188160477 crossrefType "journal-article" @default.
• W3188160477 hasAuthorship W3188160477A5010216956 @default.
• W3188160477 hasAuthorship W3188160477A5016095722 @default.
• W3188160477 hasAuthorship W3188160477A5016115173 @default.
• W3188160477 hasAuthorship W3188160477A5018382697 @default.
• W3188160477 hasAuthorship W3188160477A5020773624 @default.
• W3188160477 hasAuthorship W3188160477A5034705511 @default.
• W3188160477 hasAuthorship W3188160477A5051525187 @default.
• W3188160477 hasBestOaLocation W31881604771 @default.
• W3188160477 hasConcept C121608353 @default.
• W3188160477 hasConcept C126322002 @default.
• W3188160477 hasConcept C142724271 @default.
• W3188160477 hasConcept C188816634 @default.
• W3188160477 hasConcept C20417620 @default.
• W3188160477 hasConcept C2776235491 @default.
• W3188160477 hasConcept C2779466945 @default.
• W3188160477 hasConcept C2780192828 @default.
• W3188160477 hasConcept C2989005 @default.
• W3188160477 hasConcept C71924100 @default.
• W3188160477 hasConceptScore W3188160477C121608353 @default.
• W3188160477 hasConceptScore W3188160477C126322002 @default.
• W3188160477 hasConceptScore W3188160477C142724271 @default.
• W3188160477 hasConceptScore W3188160477C188816634 @default.
• W3188160477 hasConceptScore W3188160477C20417620 @default.
• W3188160477 hasConceptScore W3188160477C2776235491 @default.
• W3188160477 hasConceptScore W3188160477C2779466945 @default.
• W3188160477 hasConceptScore W3188160477C2780192828 @default.
• W3188160477 hasConceptScore W3188160477C2989005 @default.
• W3188160477 hasConceptScore W3188160477C71924100 @default.
• W3188160477 hasIssue "Supplement 3" @default.
• W3188160477 hasLocation W31881604771 @default.
• W3188160477 hasOpenAccess W3188160477 @default.
• W3188160477 hasPrimaryLocation W31881604771 @default.
• W3188160477 hasRelatedWork W108895284 @default.
• W3188160477 hasRelatedWork W1529340973 @default.
• W3188160477 hasRelatedWork W1982503259 @default.
• W3188160477 hasRelatedWork W1983636976 @default.
• W3188160477 hasRelatedWork W2037411085 @default.
• W3188160477 hasRelatedWork W2088520467 @default.
• W3188160477 hasRelatedWork W2094977608 @default.
• W3188160477 hasRelatedWork W2125911452 @default.
• W3188160477 hasRelatedWork W4313530623 @default.
• W3188160477 hasRelatedWork W2519753992 @default.
• W3188160477 hasVolume "206" @default.
• W3188160477 isParatext "false" @default.
• W3188160477 isRetracted "false" @default.
• W3188160477 magId "3188160477" @default.
• W3188160477 workType "article" @default.